Mon, Dec 22, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

Systematic hedge fund group Cantab Capital names Dr Matthew Killeya and Dr Genia Diamond partners

Monday, April 08, 2013

Dr. Ewan Kirk
Opalesque Industry Update - Cantab Capital Partners, the systematic global macro manager has announced that Dr Matthew Killeya (Senior Scientist) and Dr. Genia Diamond (Head of Business Development), have been named partners in the firm.

The announcement is in recognition of Dr. Killeya’s and Dr.Diamond’s contribution to Cantab’s business success and growth. Genia has lead the Investor Relations team that has overseen Cantab’s assets increase fivefold to USD 5,3 billion since 2011.

Matthew’s primary focus is on investment strategy development, having contributed strategies in all three of the clusters within the portfolio (momentum, value and short term).

Commenting on the move, Dr. Ewan Kirk said: “Our investors know that we take both our investment models and investor relations immensely seriously. Both Genia and Matthew have contributed significantly to these respective functions, as well as the overall development of Cantab. As a result we are truly pleased they have accepted our offer to join the partnership.”

Press release

Cantab Capital Partners LLP is a $5.3 billion total assets under management systematic global macro manager based in Cambridge, England. Cantab was founded in 2006 by Dr Ewan Kirk (ex-Goldman Sachs), Erich Schlaikjer (ex-Goldman Sachs) and Chris Pugh (ex-KBC). Dr Tom Howat became a Partner in 2011. The investor base is 60% institutional, 35% fund of funds, and 5% family offices/high net worth individuals. www.cantabcapital.com

Dr Genia Diamond – Head of Business Development
Genia leads the team responsible for all investor-related activities helping to further expand the firm’s reputation and place amongst investors globally.

Genia joined Cantab from OMAM UK and prior to that she was at Solent Capital and BlueCrest Capital. She started her career in asset management as a senior HF researcher at PAAMCO. Genia has a PhD in linguistics from the Moscow State University, an MBA from Erasmus University in the Netherlands and achieved an MA (honours) in Linguistics & Culture Studies from the Moscow State University.

Dr Matthew Killeya – Senior Scientist
Matthew works on all aspects of programme and portfolio construction and has driven developments in these areas, including contributing several new strategies to the portfolio.

More recently Matt’s focus has been on short term execution algorithms and strategies to trade options as a natural diversifier to the futures strategies.

Previously Matt was a senior managing researcher at Winton Capital Management for five years. Matt has a PhD in Bayesian statistics from Durham University. Prior to that, Matt obtained a first class Master of Mathematics degree, also from Durham University.

Bg

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for